Although the anti-CTLA-4xSIRPα construct has less binding affinity toward CTLA-4, it was more effective than anti-CTLA-4 plus anti-CD47 combination treatment in depleting highly immunosuppressive ICOShigh intra-tumoral Tregs and reducing tumor burden in colorectal cancer mouse models. Here, CTLA4 is linked to neoplasm.